Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas

John H. Edmonson, Randolph S. Marks, Jan C. Buckner, Michelle R. Mahoney

Research output: Contribution to journalArticle

93 Scopus citations

Fingerprint Dive into the research topics of 'Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas'. Together they form a unique fingerprint.

Medicine & Life Sciences